Biota Pharmaceuticals

Biota Pharmaceuticals Inc. is focused on the discovery and development of products to treat serious viral respiratory infectious diseases. The company has two late-stage product candidates: vapendavir, a potent, broad-spectrum capsid inhibitor of enteroviruses for the treatment of human rhinovirus-infected patients with underlying respiratory illnesses, such as moderate to severe asthma and chronic obstructive pulmonary disease; and laninamivir octanoate, which is a one-time, inhaled treatment for influenza A and B infections. Biota has also completed IND-enabling studies for BTA-C585, an orally bioavailable F-protein inhibitor in development for the treatment of respiratory syncytial virus infections and anticipates initiating clinical trials of BTA-C585 in Q3/15.